Le BPA estimée Q/Q de Bioline Rx Ltd est 0.00%
Le taux de croissance prospectif du BPA trimestriel, d'une année à l'autre , correspond à l'augmentation estimée du BPA d'une entreprise pour le prochain trimestre par rapport à la performance d'un trimestre précédent.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m